Axon Enterprise, Inc. (NASDAQ:AXON) Short Interest Update

Axon Enterprise, Inc. (NASDAQ:AXON) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 2,420,000 shares, a drop of 6.9% from the January 15th total of 2,600,000 shares. Based on an average daily volume of 894,900 shares, the days-to-cover ratio is currently 2.7 days.

Analyst Upgrades and Downgrades

AXON has been the topic of several research analyst reports. Northland Securities raised their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. TD Cowen initiated coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price target on the stock. Robert W. Baird raised their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Finally, JMP Securities raised their price target on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average target price of $542.15.

Axon Enterprise Trading Up 2.8 %

Shares of AXON stock opened at $683.41 on Monday. Axon Enterprise has a 12-month low of $260.27 and a 12-month high of $698.67. The company has a market capitalization of $52.11 billion, a P/E ratio of 176.59, a P/E/G ratio of 6.79 and a beta of 1.05. The firm has a 50-day moving average price of $623.22 and a 200 day moving average price of $509.17. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Insider Activity

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the transaction, the director now owns 6,929 shares in the company, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeffrey C. Kunins sold 2,304 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $654.79, for a total transaction of $1,508,636.16. Following the transaction, the insider now owns 128,542 shares in the company, valued at $84,168,016.18. This represents a 1.76 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,711 shares of company stock worth $5,631,561. 6.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors have recently modified their holdings of the stock. Prestige Wealth Management Group LLC raised its stake in shares of Axon Enterprise by 115.8% in the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 44 shares during the last quarter. New Wave Wealth Advisors LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter worth approximately $40,000. Brooklyn Investment Group acquired a new stake in shares of Axon Enterprise during the 3rd quarter worth approximately $41,000. Y.D. More Investments Ltd acquired a new stake in shares of Axon Enterprise during the 4th quarter worth approximately $45,000. Finally, Planning Capital Management Corp grew its position in shares of Axon Enterprise by 83.3% during the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock worth $48,000 after buying an additional 55 shares during the period. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.